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Summary We analysed the frequency of p53mRNA overexpression in a series of 109 primary colorectal carcinomas and its association with
p53 gene mutation, which has been correlated with short survival. Sixty-nine of the 109 cases (63%) demonstrated p53 mRNA over-
expression, without any correlation with stage or site of disease. Comparison with p53 gene mutation indicated that, besides cases in which
p53 gene mutation and p53 mRNA overexpression were either both present (40 cases) or both absent (36 cases), there were also cases in
which p53 mRNA was overexpressed in the absence of any mutation (29 cases) and those with a mutant gene in which the mRNA was not
overexpressed (four cases). Moreover, the mutant p53 tumours exhibited an increase of p53 mRNA expression, which was significantly
higher in tumours expressing the mutated allele alone than in tumours expressing both wild- and mutated-type alleles. These data (1) show
that p53 mRNA overexpression is a frequent event in colorectal tumours and is not predictive of the status of the gene, i.e. whether or not a
mutation is present; (2) provide further evidence that p53 protein overexpression does not only result from an increase in the half-life of
mutated p53 and suggest that inactivation of the p53function in colorectal cancers involves at least two distinct mechanisms, including p53
overexpression and/or mutation; and (3) suggest that p53mRNA overexpression is an early event, since it is not correlated with Dukes' stage.
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p53 gene mutation with or without allelic loss has been considered
to be the commonest alteration found in sporadic non-familial
cancer (Vogelstein, 1990). This alteration occurs in a wide variety
of tumour types, including solid and haematopoietic tumours
(Hollstein et al, 1991). Furthermore, humans who inherit germline
p53 mutations are prone to the development of cancer (Marklin et
al, 1990; Srivastava et al, 1990).
The wild-type p53 appears to function as a cell-growth
suppressor and may play an important role in genomic stability
and DNA repair (Zambetti et al, 1993). Wild-type p53 transacti-
vates the WAFI/p21 gene (El-Deiry et al, 1993; Harper et al,
1993), whose protein product prevents exit from the G,-phase by
inhibiting cyclin/Cdk complexes and, in parallel, blocks replica-
tive DNA synthesis by binding to proliferating cell nuclear antigen
(PCNA) (Dulic et al, 1994; Waga et al, 1994). When DNA is
altered, the cell cycle is blocked in G,-phase, allowing time for
repair (Kastan et al, 1991, 1992). If the DNA damage is too great,
the cell is engaged in the apoptosis pathway and is subsequently
deleted from the tissue (Clarke et al, 1993; Lowe et al, 1993).p53,
therefore, acts as 'the guardian of the genome' (Lane, 1992).
However, the molecular mechanism ofwild-type p53 action is not
fully understood. The p53 protein has been shown to activate
several genes by interacting with specific DNA sequences, such
as the promoter of muscle specific creatine kinase (Weintraub et
al, 1991) and the third intron of the GADD-45 gene, which is
induced after gamma irradiation (Papathanasiou et al, 1991). A
consensus p53 DNA-binding site has been derived from these
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studies (Kern et al, 1991; El-Deiry et al, 1992; Funke et al, 1992).
Wild-typep53 has also been implicated in the transcriptional inhi-
bition of several genes involved in cell growth: c-myc (Moberg et
al, 1992), retinoblastoma susceptibility gene (Shiio et al, 1992),
multidrug resistance gene-I (Chin et al, 1992), proliferating cell
nuclear antigen (Subler et al, 1992), c-fos, interleukin 6, c-jun and
hsc70, a member of the heat shock family (Ginsberg et al, 1991;
Santhanam et al, 1991; Agoff et al, 1993). This inhibitory effect
might be caused by a direct action on the TATA box machinery
(Liu et al, 1993; Thut et al, 1995). p53 was also found to be able
to stimulate its own transcription, but was unable to bind directly
the specific sequences, which have been identified in the p53
promoter (Deffie et al, 1993).
In colorectal cancer, p53 mutations and allelic losses on 17p are
genomic alterations that occur as late events in tumour progression
(Baker et al, 1990; Fearon et al, 1990). p53 gene mutations have
been associated with poor prognosis in human breast carcinomas
(Thorlacius et al, 1993) and in non-small-cell lung cancer (Horio
et al, 1993). In colorectal cancer, a strong correlation has been
observed between the presence of a mutation and short survival
(Hamelin et al, 1994). In contrast to previous findings (Kern et al,
1989), when tumours were classified according to their histolog-
ical stage, a multivariate Cox model analysis showed that p53
mutation, rather than 17p allelic losses, was the only independent
prognostic factor (Hamelin et al, 1994). Immunohistochemistry
(IHC) studies have indicated that mutated p53 is overexpressed
in premalignant head and neck lesions (Shin et al, 1994),
oesophageal squamous cell carcinomas (Wagata et al, 1993),
ovarian cancer (Kupryjanczyk et al, 1993), breast cancer (Faille et
al, 1994) and hepatocellular carcinoma (Wolkmann et al, 1994). In
colorectal cancer, overexpression of p53 protein has been corre-
lated with poor short-term prognosis (Yamaguchi et al, 1992;
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Most authors attributed p53 protein overexpression to an
increase in its half-life owing to the conformational changes
induced by mutations (Zambetti et al, 1993), but this mechanism is
not relevant in the case of wild-type overexpression. In order to
define more clearlyp53 gene expression, we analysed in this study
p53 mRNA expression in 109 colorectal carcinomas by the use of
a semi-quantitative reverse transcription - polymerase chain reac-
tion (RT-PCR) technique and examined its relationship to p53
mutation.
MATERIALS AND METHODS
Materials
This study was performed on a series of 109 specimens obtained
from patients undergoing resection of colorectal adenocarcinoma
between January 1992 and November 1994. Tumour and adjacent
normal mucosa samples from the same patient were immediately
L - I I I I I I I I collected for analysis in the pathology department, frozen in liquid
20 22 24 26 28 30 32 36 40 nitrogen and stored at-80°C. Before DNA and RNA isolation, the
quality oftumours and normal samples in each case was evaluated
Cycle by examination ofcryostat sections stained with haemalun.
B Patients with familial adenomatosis orhereditary non-polyposis
0 colorectal cancer with a highly penetrant genetic predisposition to
colorectal cancer were excluded from this study. This series
included 63 men and 46 women (mean age 64.5 ± 14.5 years).
Twenty-six tumours out of the 109 studied were right-sided
(caecum, ascending and transverse colon), 49 were left-sided
lo . / (descending colon and sigmoid) and 34 were located in the rectum.
According to the modified Dukes' staging system, 15 were Dukes'
stage A (13.8%), 36 were Dukes' stage B (33%), 34 were Dukes'
stage C (31.2%) and 24 were Dukes' stage D (22%).
10
1
a i a a
22 24 26 28 30 32 34 36
Clinical stage and tumour site
Of the 109 tumours studied, 60 (55%) were associated with nodal
involvement or distant metastasis. A significant association was
observed between tumour staging and location (P=0.01). Tumours
of the rectum exhibited a higher proportion of advanced Dukes'
stage (C+D = 71%) than those located in the distal (45%) or prox-
imal colon (46%).
Cycle
Figure 1 Determination of the optimal number of amplification cycles for
quantification of p53 and ,B-actin mRNA. fI-actin (@) and p53 (U, A) PCR
products coming from eight normal mucosa (A) and their corresponding
tumour samples (B) were subjected to 6% PAGE, and the intensity of
fluorescence product for each cycle was automatically measured, in arbitary
units (AU) (mean value ± s.d.). For tumour samples, p53 PCR products were
obtained from two patients with (U) or without (A) p53 mRNA overexpression
Auvinen et al, 1994). However, the literature concerning the prog-
nostic value ofp53 immunoreactivity is controversial, as the results
ofIHC assays cannot be accepted as evidence ofp53 gene mutation
(Battifora et al, 1994). In addition, there is no clear picture
concerning the significance of wild-type overexpression observed
in several studies on colorectal adenomas (Pignatelli et al, 1992;
Pignatelli et al, 1992; Tominaga et al, 1993) and demonstrated in
anaplastic astrocytomas (Lang et al, 1994), breast cancer (Moll et
al, 1992), melanomas (Castresanaetal, 1993), testis cancer(Penget
al, 1993) and hepatic tumours ofchildhood (Kennedy et al, 1994).
Preparation of DNA and RNA
DNA was extracted from each tumour and normal mucosa sample
by treatment with sodium dodecyl sulphate (SDS), proteinase K
and phenol - chloroform according to Fritsch et al (1989). RNA
was isolated, using 50 mg of frozen powdered sample, with
RNAzol (Bioprobe Corporation, France), according to the manu-
facturer's recommendations. RNA and DNA concentrations were
quantified by spectrophotometry and determined to be intact by
migration on 1% agarose gels and staining with ethidium bromide.
Reverse transcription
This was carried out in a20-gl reaction volume containing 500 gM
dNTP, 10 mM DTT, 0.5 U gl-' RNAasin (Promega Corporation);
5 JM random hexamers and 10 jg tl-' reverse transcriptase (Gibco
BRL, Bethesda, MD. USA). RNA extracts were heated for 5 min
at 70°C and cooled on ice before being added (1 jig) to the reaction
mixture.
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Table 1 Primer sequences for p53 analysis
Name Site Sequences
p53 (RT-PCR) Nucleotide numbers
Set 1 Primer 1 Sense 168-186 5'-ACA CGC TTC CCT GGA TTG G-3'
Primer 2 Antisense 616-634 5'-GGT CTT GGC CAG TTG GCA A-3'
Set 2 Primer 3 Sense 548-571 5'-GGC TTC TTG CAT TCT GGG ACA GCC-3'
Primer 4 Antisense 964-985 5'-CAG TGT GAT GAT GGT GAG GAT G-3'
Set 3 Primer 5a Sense 887-907 5'-GTT GGC TCT GAC TGT ACC ACC-3'
Primer 6 Antisense 1223-1246 5'-CAG CTC TCG GAA CAT CTC GAA GCG-3'
Set 4 Primer 7 Sense 1087-1104 5'-GAA AGG GGA GCC TCA CCA-3'
Primer 8 Antisense 1411-1427 5'-GCT GTC AGT GGG GAA CAA-3'
p53 (DNA) Intron number
Set 5 Primer 9 Sense Intron 4 5'-TTC AAC TCT GTC TCC TTC CT-3'
Primer 10 Antisense Intron 6 5'-TTA ACC CCT CCT CCC AGA AGA-3'
Set 6 Primer 11 Sense Intron 6 5'-GTC TCC CCA AGG CGC ACT GG-3'
Primer 12 Antisense Intron 7 5'-GAT GTG ATG AGA GGT GGA T-3'
Set 7 Primer 13 Sense Intron 7 5'-TTC CTT ACT GCC TCT TGC TT-3'
Primer 14 Antisense Intron 9 5'-CCC MG ACT TAG TAC CTG AA-3'
,B-Actin (RT-PCR) Exon number
Set 8 Primer 15a Sense Exon 3 5'-CGT GGA TGC CAC AGG ACT CC-3'
Primer 16 Antisense Exon 4 5'-ATC ATG TTT GAG ACC TTC AA-3'
aFluorescent primer when required.
PCR amplification
All primers and probes, used to optimize RT-PCR procedures,
were synthesized using a 391 DNA synthesizer (Applied Bio-
system, Foster City, CA, USA), followed by high-performance
liquid chromatography. The fluorescent-labelled primers, used to
measure mRNA levels and to sequence the PCR products, were
purchased from Genset Corporation (France). The sequences of
the various primers are given in Table 1. Reverse-transcribed
cDNA (5 ,l, 0.25 jig) was subjected to PCR amplification with
two sets ofp53 and P-actin (internal standard) primers. PCR reac-
tion was performed in 25 gl ofreaction medium containing 10 mM
Tris-HCL, pH 8.3, 50 mm magnesium chloride, 0.001% gelatin,
0.05 U Taq DNA polymerase (Beckman, USA) and 0.5 ,UM ofeach
primer. Each cycle consisted of 15 s denaturing at 94°C, 15 s
annealing at 58°C and 30 s extension at 72°C. Negative controls
were performed with RNA samples amplified without reverse
transcriptase. Cycling was performed in a Perkin-Elmer 9600 ther-
mocycler (Cetus).
Quantitation of PCR products
The optimal number of cycles of amplification to allow quantita-
tion ofp53 and 3-actin gene PCR products was determined using
primers 5 and 6 for p53 and 15 and 16 for P-actin, the primers 5
and 15 being coupled to a fluorophore. The PCR products for each
cycle were subjected to 6% polyacrylamide gel electrophoresis
(PAGE). The size of the PCR products, as well as the intensity of
the fluorescence, were automatically measured and integrated
using the genescan software (version 1.2) in an ABI model 373
(Applied Biosystem). We obtained a linear increase in the signal
between 22 and 26 cycles forp53 and f-actin in tumour and adja-
cent normal mucosa samples. To test the reproducibility and
linearity of the data, eight different samples (tumour and their
adjacent normal mucosa samples) were chosen randomly (Figure
1). The appropriate number ofPCR cycles for detection and quan-
tification ofp53 and ,B-actin DNA fragments lay between 20 and
26 cycles and first-strand cDNA was therefore used directly for 26
cycles of PCR amplification. So, the amount ofp53 mRNA was
expressed in arbitrary units (AU), which represented the value of
the ratio between the fluorescent signal ofp53 cDNA and P-actin
cDNA after 26 cycles.
p53 cDNA sequencing
All samples showing a highp53 mRNA level were tested to deter-
mine the entire coding sequence of thep53 cDNA. After an addi-
tional reverse transcription, fourdifferent PCRs (100g1 ofreaction
mixture) with each set ofprimers 1 to 4 (Table 1) were performed
in order to amplify overlapping fragments ofthe total cDNA. After
35 cycles of PCR, the primers and oligonucleotides were recov-
ered from the reaction mixture using acentricon 100 microconcen-
trator (Amicon, Beverly, MA, USA). Specific p53 amplification
products were identified by electrophoresis on 2% agarose gels.
The PCR products (100 ng) were subjected to sequencing reac-
tions using the Prism reaction dideoxyterminator kit according to
the protocol supplied by the manufacturer (Applied BioSystem).
Taq sequencing reactions were carried out in a Perkin-Elmer ther-
mocycler 9600 as follows: 30 s at 96°C, 15 s at 50°C and 4 min at
60°C for 25 cycles. Extended fragments were purified from non-
incorporated nucleotides and primers through quick TM spin
columns (Boehringer). The reaction mixtures were then dried,
resuspended in 4 gl of dionized formamide: 50 mM EDTA, pH
8.0, heated for 2 min at 90°C, transferred on ice and loaded imme-
diately onto a 6% denaturating polyacrylamide gel. Gels were run
for 12 h at 30 W constant power on an ABI model 373 A auto-
mated DNA sequencer.
p53genomic DNA sequencing
Samples withoutp53 mRNA overexpression were sequenced after
amplification of genomic DNA. In these cases, the primers used
for DNA amplification are summarized in Table 1. A total ofthree
different polymerase chain reactions were used to screen the entire
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Table 2 p53 mRNA levels among the 69 tumours showing overexpression
Number of tumours p53 mRNA levela
Without p53 mutation 29 0.56 ± 0.32
With p53 mutation 40
Presence of wild transcript 21 0.56 ± 0.31
Absence of wild transcript 19 0.86 ± 0.47
aRatio between the amount of p53to ,B-actin RT-PCR products at 26 cycles,
expressed in arbitrary units as described in Materials and methods, values
are the means ± s.d. F269 (one-way analysis of variance) = 4.94; P= 0.01.
Table 3 Relationship between p53gene alterations and clinicopathological
features
Absence of expression
Mut- Mut+ of wild allele among mut +
n(%) n(%) n(%)
Dukes' stage
A 10 (15) 5 (11) 2/5 (40)
B 24 (37) 12 (27) 5/12 (42)
C 20 (31) 14 (32) 6/14 (43)
D 11 (17) 13 (30) 7/13 (54)
Total 65 (100) 44 (100)
Intestinal site
Proximal colon 18 (26) 8 (18) 2/8 (25)
Distal colon 27 (44) 22 (50) 11/22 (50)
Rectum 20 (31) 14 (32) 6/14 (43)
Total 65 (100) 44 (100)
mut +, with p53 mutation, mut -, without p53 mutation.
<
( 1.0 .
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Figure 2 Relative expression of p53 mRNA transcripts in normal mucosa
and colorectal carcinoma according to Dukes' stage. p53 mRNA level was
expressed in arbitrary units as described in Materials and methods
Normal mucosa 0.08 ± 0.06a n= 39
Colorectal carcinoma according to Dukes' stage
A p53 mRNA level < 0.2 0.11 +0.08 n= 6
>0.2 0.51 ±0.49 n= 9
B p53 mRNA level < 0.2 0.09 ± 0.06 n = 14
> 0.2 0.62 ± 0.37 n= 22
C p53 mRNA level < 0.2 0.10 ± 0.07 n= 10
> 0.2 0.58 ± 0.36 n= 24
D p53 mRNA level < 0.2 0.10 ± 0.07 n= 10
> 0.2 0.64±0.42 n= 14
aValues are means ± s.d.
coding sequence contained within exons 5-8 and their corre-
sponding splicejunctions.
Cell line
The human colorectal cancer cell line, HT29, with a known p53
point mutation at codon number273, was used as apositive control
for sequencing and RT-PCR analysis ofp53 mRNA expression.
Statistical analysis
Results are expressed as the mean ± standard deviation. The mean
p53 mRNA for each of the subgroups of tumours was compared
by one-way analysis ofvariance. The chi-square (%2) test ofsignif-
icance was used to analyse the frequency.
RESULTS
p53 mRNA levels
The p53 mRNA content from colorectal carcinoma and adjacent
normal mucosa samples was examined by a semi-quantitative
RT-PCR procedure, and the results were normalized against theP-
actin mRNA content observed in the same samples. In adjacent
mucosa, the relative level ofp53 mRNA remained very low, i.e.
0.08 ± 0.06 AU (n = 40) and was always lower than 0.20 AU
(Figure 2). This value was therefore chosen as the upper limit of
the normal p53 mRNA level. In contrast to normal tissue, thep53
mRNA level observed in tumour tissue was distributed over a
wide range of values with an upper limit of 1.55 AU. Forty
tumours out of 109 (37%) exhibited mRNA values in the normal
range, i.e. lower than 0.20 AU. p53 mRNA overexpression, i.e.
higher than 0.20 AU, was observed in 69 out of 109 tumour
samples (63%) with a mean value of0.64 AU (s.d. 0.38).
Comparison between p53 mRNA expression and gene
mutation
In the 69 tumours that overexpressed p53 mRNA, an absence of
mutation was observed in the coding sequence ofp53 mRNA in 29
cases (42%). In 21 out of40 samples in which mutated mRNAp53
was observed, we also demonstrated coexpression ofthe wild-type
allele. This is visible on the sequence spectrum by the presence of
two bases at the same position (data not shown). However, it is
impossible to sequencep53 cDNA from normal tissue by RT-PCR.
The level of p53 mRNA was significantly higher in tumours
expressing the mutated-type allele alone (0.86 ± 0.47 AU) than in
tumours also expressing the wild-type allele (0.56 ± 0.31 AU) or in
tumours with non-mutatedp53 (0.56 ± 0.32 AU) (Table 2). In four
of the 40 tumours without mRNA overexpression, we found p53
gene mutation associated with wild-type allele expression.
Relationship between p53 gene alterations and
clinicopathological features
The frequency ofmutation was not statistically different according
to the Dukes' stage (P=0.40) or the location (P=0.5) (Table 3). The
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Table 4 List of individual tumours showing p53 mutations in colorectal cancer
Tumour Sitea Dukes' Expression of Exon Codon Base change Amino acid change p53 mRNA level
stage wild alleleb number number
Normal mucosac Tumoursc
121 R
44 PC
37
140
2
120
46
160
173
194
122
11
148
193
108
125
104
157
13
72
88
96
150
138
97
147
DC
DC
R
R
PC
PC
DC
DC
R
DC
DC
DC
DC
R
R
R
PC
R
R
R
DC
DC
DC
PC
C
C
2-3-4
4
D
A
C
D
B
B
B
C
B
D
B
B
D
B
B
A
B
C
C
B
A
A
D
C
199 R C
155 R C
156 R C
71 DC D
41 DC C
35 DC D
36 DC D
43 DC B
48 PC A
77 PC D
143 DC D
151 DC D
62 DC D
129 R B
32 DC C
164 PC D
9 DC C
186 DC C
5
5
5
5
5
5
5
5
5
6
6
6
6
6
7
7
7
7
7
7
7
7
7
7
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
1 - 43 1 -* 129 Another polypeptide sequence
in N terminus
33 - 48 97 -+ 144 Another polypeptide sequence
between aa 33 and 48
143 GTG -GCG V- A
143 GTG-GAG V* E
161 GCC-ACC A-T
167 CAG-CGG E-R
168 CAC -CGC H- R
175 CGC-CAC R- H
175 CGC-GGC R* G
177-179 Deletion of Deletion of PHH
CCC CAC CAT
179 CAT-TAT H-Y
194 CTT-CCT L- P
196 CGA -TGA R-Stop
196 CGA-4TGA R-Stop
205 TAT-GAT Y-D
220 TAT-TGT Y-C
245 GGC-GAC G- D
245 GGC-TGC G-C
248 CGG-CAG R-Q
248 CGG-TGG R- W
248 CGG-CAG R-Q
248 CGG-CAG R*Q
248 CGG-TGG R>W
248 CGG-CAG R- Q
255 ATC-TTC o F
257 Deletion Frameshift changing aa
sequence (stop codon 344)
CTG -* TG
7 259 Insertion
GAC -* GTAC
8 263 Insertion of
5b: AA [GGTAA] T
8 266 GGA-GTA
8 272 GTG-ATG
8 272 GTG-TTG
8 273 CGT -TGT
8 273 CGT -TGT
8 273 CGT -TGT
8 273 CGT CAT
8 273 CGT CAT
8 273 CGT - CAT
8 273 CGT -TGT
8 273 CGT -TGT
8 273 CGT -TGT
8 274 GTT- CTT
8 280 Deletion
AGA -* GA
8 301 Deletion
CCA - CA
9 306 CGA -TGA
Frameshift changing aa
sequence (stop codon 263)
Frameshift changing aa
sequence (stop codon 344)
G - V
V - M
V - L
R - C
R - C
R - C
R - H
R - H
R - C
R - C
R - C
V - L
Frameshift changing aa
sequence (stop codon 344)
Frameshift changing aa
sequence (stop codon 344)
R -* stop
0.07 0.24
0.09
ND
0.17
0.01
0.05
0.11
0.13
0.04
ND
0.05
ND
0.06
ND
ND
ND
ND
ND
0.01
ND
ND
0.12
0.18
0.10
0.00
0.06
0.48
0.48
1.54
1.54
0.40
0.33
1.32
0.62
0.62
0.45
0.67
0.98
0.35
0.25
1.22
0.94
0.77
0.36
0.27
0.46
0.30
1.49
0.10
0.10
1.42
ND 0.21
ND 0.70
ND
ND
ND
ND
ND
0.08
ND
ND
ND
0.18
ND
ND
ND
0.02
0.10
ND
1.13
0.56
0.31
0.31
0.97
0.25
0.77
0.37
1.40
1.15
0.70
0.69
0.38
0.10
0.10
0.78
aPC, proximal colon; DC, distal colon; R, rectum. bExpression of wild allele: +, wild and mutated-type alleles are expressed together; -, mutated-type allele is
expressed alone. cRatio between the amount of p53to 3-actin RT-PCR products at 26 cycles. ND, not determined. aa, amino acid.
proportion of mutated tumours not expressing the wild-type allele p53 gene mutation
was roughly the same at each Dukes' stage. Conversely, this Table 4 provides the exact DNA alteration observed in 44 tumours
proportion varied according to site: 25% of the tumours did not and its location on the gene. The histological grade andp53 mRNA
express the wild-type allele in the proximal colon vs 50% and 43% expression in these tumours and their adjacent normal tissues are
in distal colon and rectum respectively, but this difference was not also shown. Among the 36 substitutions of a single base pair, 28
statistically significant (P=0.47) (Table 3). (77.8%) were G:C *- -* A:T transitions (21 occurring at CpG
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dinucleotides), while eight of them (22.2%) were transversions.
Three point mutations created a stop at codons 148, 186 and 193,
while 33 out of 44 (75%) missense mutations were detected: 21
were found at codons 175, 245, 248, 273 and 272 located in major
mutational 'hotspots', frequently affected in colorectal cancer
(Greenblatt et al, 1994). Nine of these mutations concerned codon
number 273 (six CGT -> TGT, R -4 C and three CGT -> CAT, R
-> H); in these tumours, the p53 mRNA level was either 0.46 +
0.22 AU when the wild-type allele was expressed or 0.87 ± 35 AU
when not expressed. These results are identical to those obtained
with respect to all mutated tumours expressing the wild-type allele
(or not) (Table 2). Six of the missense mutations affected codon
number 248 (four CGG -- CAG, R -e Q and two CGG -> TGG, R
-e W), two of the missense mutations affected codon number 175
(CGC -X CAC, R -4 H and CGC -o GGC, R -e G) and the codon
number 245 (GGC -* GGA, G -* D and GGC -* TGC, G -e C).
We also found two mutations at codon number 272 (GTG -> ATG,
V -- M andGTG -> TTG, V -4 L).
Eight mutations created major rearrangements of the mRNA
reading frame (Table 4), four of them were insertions or deletions
of one basepair. Deletions of cytosine 983 at codon 257 (tumour
147), adenine 1052 at codon 280 (tumour 164) and cytosine 1115
at codon 301 (tumour 9) gave three putative p53 proteins
composed of 343 amino acids differing in their C-terminus.
Insertion of a thymine after the guanine 989 at codon 259 (tumour
199) gave a putative shorter polypeptide composed of 262 amino
acids. In four cases, more markedrearrang'ements were observed: a
large rearrangement (tumour 121) in the N-terminus (from
nucleotide 1 to 129), a non-homologous recombination of43 base-
pairs after nucleotide 97 (tumour 44), a deletion of nine bases
(amino acids 177 to 179, PHH) (tumour 194) and an insertion of
five bases after nucleotide 1002 at codon 263 (tumour 155) giving
a p53 protein composed of343 amino acids. These eight rearrange-
ments all concerned advanced Dukes' stage (seven were Dukes'
stage C and one was Dukes' stage D).
DISCUSSION
In this series of 109 primary colorectal carcinomas, we observed
pS3 mRNA overexpression in 63% of the cases. This overexpres-
sion occurred without any correlation with the stage or site of the
disease. The mean level ofp53 mRNA expression is five- to sixfold
higher in these tumours than in adjacent normal mucosa. Some
tumours showed high p53 mRNA levels, while others showed a
slight increase. In the latter case,p53 mRNA may either be weakly
expressed in all tumour cells or highly expressed in a few tumour
cells owing to tumour heterogeneity. Indeed, it has been described
that the tumourcell staining varied in extent and intensity when p53
protein is detected by IHC (Zeng et al, 1994). Our results clearly
demonstrate that p53 regulation may occur at a pretranslational
step, involving either an increase in p53 gene expression and/or
stabilization of its mRNA. Our findings confirm earlier reports,
which showed an elevated level ofp53 transcripts in 28 (Gope et al,
1991) and 25 (Lothe et al, 1992) cases, 70% and 66% of tested
tumours overexpressed p53 respectively. In these studies, p53
mRNA quantification was performed by Northern blot analysis.
When DNA sequencing was performed, 44 tumours (40%)
exhibited p53 mutation. Our data on the prevalence and spectra of
p53 mutations in colorectal cancer agree with those obtained from
960 cases compiled by Greenblatt et al (1994). However, the most
striking difference between the two studies concerns the number
of non-missense type mutations, which accounted for 18% of
mutations in our study vs 8% in Greenblatt's study. Among the 36
substitutions of a single basepair, 28 of them occurred at CpG
dinucleotides; the p53 coding region contains 39 CpG dinu-
cleotides, which are potential sites for the methylation ofcytosine.
Recently, Tornaletti et al (1995) found that the p53 sequences
along exons 5-8 were completely methylated at every CpG site,
whatever the tissue. Methylation of CpG dinucleotides is thought
to be the cause of the genetic changes occurring through sponta-
neous deamination of 5-methylcytosine (Rideout et al, 1990) and
accounted for the majority ofendogenous mutations in vertebrates
(Sved et al, 1990). In our study, mutated and wild-type alleles were
expressed simultaneously in 25 tumours, and the loss ofwild-type
allele expression was rarely observed in the proximal colon (25%)
vs 50% and 43% in the distal colon and the rectum respectively.
The rectum is a site in which a high incidence of 17p allelic loss
has been observed. These differences were not statistically signifi-
cant, and the hypothesis that genetic mechanisms leading to cancer
differ in the proximal and distal colon needs to be verified
(Delattre et al, 1989).
In 40 ofthe 44 mutated tumours, p53 mRNA levels were signif-
icantly higher in tumours expressing the mutated allele alone than
in tumours expressing both wild- and mutated-type alleles. It has
been described thatp53 stimulates its own transcription (Deffie et
al, 1993), and that some p53 mutant forms presented wild-type
transactivation activity (Levine et al, 1991). In addition, p53 can
induce transcription from an internal promoter located within the
mdm2 gene (Juven et al, 1993), whose product, MDM2 oncopro-
tein, has been identified as a negative regulator of the p53 gene.
Further, MDM2, by binding to p53, inhibits its ability to activate
transcription and may, therefore, be part of a negative feedback
loop serving to terminate signals involving the transient activation
of wild-type p53 (Oliner et al, 1992; 1993). So, when a p53 gene
mutation occurs, the absence of a negative feedback might be
responsible forp53 mRNA overexpression. The suppressor func-
tion ofwild-typep53 may also be compromised in cells containing
a mutant allele ofp53, since the formation of wild-type - mutant
p53 inactive complexes occurs (Milner et al, 1991). Thus, mutant
forms abrogate the ability of wild-type p53 to transactivate
appropiate target genes in vitro and in vivo (Farmer et al, 1992;
Kern et al, 1992), and the relative quantity of mutated to wild-type
p53 mRNA could determine the transformed phenotype, and the
result could be partial or complete loss of wild-type function. p53
mRNA overexpression can account for an elevated content of p53
protein in the absence ofp53 gene mutation. An increase in wild-
type p53 has been observed in colorectal adenomas and has been
suggested to constitute an early event in the process of adenoma
formation and carcinogenesis (Tominaga et al, 1993; Boccuzzi,
1995); our present data showing no correlation between p53
mRNA and tumour stage agree with these results. Other results
suggest that, in colorectal cancer, IHC detection of p53 protein
does not always indicate the existence of an underlying p53 gene
mutation (Dix et al, 1994). This abnormal expression of wild-type
p53 protein was also found in normal cells of a patient from a
family with a history of cancer (Barnes et al, 1992) and, more
recently, a new case of Li-Fraumeni was reported in which no
mutation in the coding sequence of the p53 gene was detected
(Birch et al, 1994). In all cases, stabilization of the p53 protein
depends on factors other than p53 gene mutation, such as (1)
binding to other molecules of cellular (mdm2 gene product) or
viral origin blockingp53 in an inactive conformation; and/or (2) its
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sequestration in a cellular compartment in which it cannot exert its
functions. Recent data have demonstrated wild-type p53 protein
accumulation in the cytoplasm of astrocytomas (Lang et al, 1994),
melanomas (Castresana et al, 1993) and testis cancer (Peng et al,
1993), and that nuclear exclusion ofp53 might also be one way of
inactivating p53 in breast cancer (Moll et al, 1992). Nuclear exclu-
sion of wild-type p53 is suggested in a study showing its cyto-
plasmic accumulation in colorectal cancers (Bosari et al, 1995)
with a higher prevalence in advanced tumours (Sun et al, 1992).
Another study has shown an increase in p53 protein according to
the stage ofcarcinomas from the rectum (Starzynska et al, 1992). In
our study, the level ofp53 mRNA did not correlate with either the
Dukes' stage or the tumour site, in accordance with previous data
showing no correlation in colorectal cancers between p53 overex-
pression detected by IHC and clinicopathological data (Yamaguchi
et al, 1992, ; Bosari et al, 1994). This lack of correlation between
p53 overexpression (either mRNA or protein) and tumour stage
suggests that it is an early event in these tumours, perhaps begin-
ning with adenoma formation (Tominaga et al, 1993).
p53 mRNA overexpression with or without p53 mutation
suggests two distinct mechanisms of inactivation leading to the
development of cancer, and that the p53 status might have impor-
tant implications for cancer therapy. The tumour-suppressing func-
tion of p53 preserves genome integrity and the p53 protein is
required for apoptosis in response to radiation-induced DNA
damage, a mechanism serving to eliminate potentially oncogenic
cells (Lee et al, 1993). The relation betweenp53 mutations and the
therapeutic response has been verified in vivo in athymic nude
mice injected with embryonic transformed fibroblasts differing in
their p53 status. Tumours expressing the wild-type p53 gene
contained a high proportion of apoptotic cells and typically
regressed after gamma radiation or doxorubicin treatment. In
contrast, wild-type p53-deficient tumours continued to grow and
contained few apoptotic cells (Lowe et al, 1994). These data show
that much benefit could be gained from identifying cancers without
p53 mutations, which are likely to respond more favourably to
drug therapy than those with mutated p53. Conversely, patients
whose tumours harbour p53 mutations might be spared from the
toxicity associated with chemotherapy agents and would be good
candidates for novel therapeutic approaches. Recently, Fujiwara et
al (1994) reported the in vivo retroviral transduction of wild-type
p53 in human lung cancer cells in an orthotopic nude mouse model
with endogenous mutatedp53. They demonstrated that cancer cell
growth can be eliminated or greatly reduced by this in vivo gene
therapy beginning 3 days after tumour cell inoculation. So, 'cancer
therapy meets p53 status (Kinzler et al, 1994).
Analysis of the level of p53 mRNA in colorectal cancer by
quantitative RT-PCR provides a rapid and sensitive method for
discriminating between tumours overexpressing p53 mRNA with
or without p53 gene mutation. This should be useful for future
anti-tumour research and for the design of therapeutic agents
specific to the inactivation process. The observation period in our
study was too short to clarify the relationship between p53 mRNA
overexpression and clinical prognosis of patients with a colorectal
carcinoma; we are following these patients.
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